A Breakthrough in Triple-Negative Breast Cancer Treatment

Learn More About Sacituzumab Govitecan

Investor Event at the 2017 San Antonio Breast Cancer Symposium

On December 6, 2017, Immunomedics hosted an investor event at the Grand Hyatt Hotel in San Antonio, TX. Click the link below to access the webcast.

An Advanced Antibody-Based Therapeutics Company

Immunomedics is committed to being a leading, innovative biopharmaceutical company, dedicated to improving patient’s health and quality of life with novel antibody–based therapeutics for the treatment of cancer, autoimmune and other serious diseases.

Our Drive to Improve Targeted Therapies of Diseases

We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.

Pipeline

We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.

Magnifying glass with people

Explore how we turn our research into reality.

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Clinical Trials